We have updated our estimates to include the reboot of the Vanguard project under the codename Kestrel. As a result, cash flows from Remedy’s projects will focus slightly more at the end of this decade. Overall, Remedy’s share valuation prices good success for future games, which we believe is also justified in light of AW2’s excellent reception. The positive momentum around AW2 is also a clear driver supporting the share in the short term. As a whole, the risk/return ratio is now too thin in the neutral scenario in line with our estimates, although the hit game option associated with each game project can change the situation quickly.